02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

582 YARROW<br />

Urticaria<br />

(2001): Uter W+, Am J Contact Dermat 12(3), 182<br />

Eyes<br />

Rhinoconjunctivitis<br />

(2001): Uter W+, Am J Contact Dermat 12(3), 182<br />

YOHIMBINE<br />

Scientific name: Pausinystalia yohimbe<br />

Family: Rubiaceae<br />

Trade <strong>and</strong> other common names: Actibane (Consolidated<br />

Midl<strong>and</strong>); Aphrodyne (Star); Yocon (Palisades); Yohimex<br />

(Kramer); Yomax<br />

Category: Rauwolfia alkaloid<br />

Purported indications <strong>and</strong> other uses: Impotence, alpha2adrenergic<br />

blocker, orthostatic hypertension<br />

Half-life: 36 minutes<br />

Clinically important, potentially hazardous interactions<br />

with: tricyclic antidepressants<br />

Reactions<br />

Skin<br />

Adverse effects (sic)<br />

(2002): Haller CA+, Adverse <strong>Drug</strong> React Toxicol Rev 21(3), 143<br />

Diaphoresis<br />

Exfoliative dermatitis<br />

(1993): S<strong>and</strong>ler B+, Urology 41, 343<br />

Lupus erythematosus<br />

(1993): S<strong>and</strong>ler B+, Urology 41, 343<br />

Other<br />

Death<br />

ZAFIRLUKAST<br />

Trade name: Accolate (AstraZeneca)<br />

Indications: Asthma<br />

Category: Leukotriene receptor antagonist<br />

Half-life: 10 hours<br />

Clinically important, potentially hazardous interactions<br />

with: CYP3A4 substrates, high protein foods<br />

Reactions<br />

Skin<br />

Allergic granulomatous angiitis (Churg–Strauss syndrome)<br />

(2007): Guilpain P+, Presse Med 36(5 Pt 2), 890<br />

(2006): Reyes-Balaguer J+, J Investig Allergol Clin Immunol<br />

16(1), 69<br />

(2003): Cakir B+, South Med J 96(7), 677<br />

(2003): Garcia-Marcos L+, <strong>Drug</strong> Saf 26(7), 483<br />

(2002): Soy M+, Clin Rheumatol 21(4), 328<br />

(1999): Green RL+, Lancet 353, 725 (2 cases)<br />

(1999): Wechsler ME+, Chest 116, 266<br />

(1999): Wechsler ME+, Lancet 353, 1970<br />

(1998): Churg J+, JAMA 279, 1949<br />

(1998): Holloway J+, J Am Osteopath Assoc 98, 275<br />

(1998): Honsinger RW, JAMA 279, 1949<br />

(1998): Katz RS+, JAMA 279, 1949<br />

(1998): Knoell DL+, Chest 114, 332<br />

(1998): Wechsler ME+, JAMA 279, 457<br />

Lupus erythematosus<br />

(1999): Finkel TH+, J Allergy Clin Immunol 103, 533<br />

Vasculitis<br />

(2002): Soy M+, Clin Rheumatol 21(4), 328<br />

Mucosal<br />

Oral ulceration<br />

(1999): Finkel TH+, J Allergy Clin Immunol 103(3), 533<br />

Other<br />

Cough<br />

(2001): Spector SL, Ann Allergy Asthma Immunol 86(6 Suppl 1), 18<br />

Myalgia/Myositis/Myopathy/Myotoxicity (1.6%)<br />

(1999): Finkel TH+, J Allergy Clin Immunol 103(3), 533<br />

ZALCITABINE<br />

Synonyms: ddC; dideoxycytidine<br />

Trade name: Hivid (Roche)<br />

Indications: Advanced HIV disease<br />

Category: Antiretroviral; Nucleoside analog reverse<br />

transcriptase inhibitor<br />

Half-life: 2.9 hours<br />

Reactions<br />

Skin<br />

Acne (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!